ID   RFWD3_HUMAN             Reviewed;         774 AA.
AC   Q6PCD5; A8K585; B2RE35; D3DUJ8; Q5XKR3; Q9H9Q3; Q9NVT4;
DT   20-FEB-2007, integrated into UniProtKB/Swiss-Prot.
DT   20-FEB-2007, sequence version 3.
DT   28-JUN-2023, entry version 167.
DE   RecName: Full=E3 ubiquitin-protein ligase RFWD3 {ECO:0000305};
DE            EC=2.3.2.27 {ECO:0000269|PubMed:26474068, ECO:0000269|PubMed:28575657, ECO:0000269|PubMed:28575658};
DE   AltName: Full=RING finger and WD repeat domain-containing protein 3;
DE   AltName: Full=RING finger protein 201;
GN   Name=RFWD3 {ECO:0000312|HGNC:HGNC:25539};
GN   Synonyms=RNF201 {ECO:0000312|HGNC:HGNC:25539};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Teratocarcinoma, and Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X., Xie G.,
RA   Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A., Bajorek E.,
RA   Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J., Buckingham J.M.,
RA   Callen D.F., Campbell C.S., Campbell M.L., Campbell E.W., Caoile C.,
RA   Challacombe J.F., Chasteen L.A., Chertkov O., Chi H.C., Christensen M.,
RA   Clark L.M., Cohn J.D., Denys M., Detter J.C., Dickson M.,
RA   Dimitrijevic-Bussod M., Escobar J., Fawcett J.J., Flowers D., Fotopulos D.,
RA   Glavina T., Gomez M., Gonzales E., Goodstein D., Goodwin L.A., Grady D.L.,
RA   Grigoriev I., Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E.,
RA   Huang W., Israni S., Jett J., Jewett P.B., Kadner K., Kimball H.,
RA   Kobayashi A., Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y.,
RA   Lowry S., Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L., Rash S.,
RA   Retterer J., Ricke D.O., Robinson D.L., Rodriguez A., Salamov A.,
RA   Saunders E.H., Scott D., Shough T., Stallings R.L., Stalvey M.,
RA   Sutherland R.D., Tapia R., Tesmer J.G., Thayer N., Thompson L.S., Tice H.,
RA   Torney D.C., Tran-Gyamfi M., Tsai M., Ulanovsky L.E., Ustaszewska A.,
RA   Vo N., White P.S., Williams A.L., Wills P.L., Wu J.-R., Wu K., Yang J.,
RA   DeJong P., Bruce D., Doggett N.A., Deaven L., Schmutz J., Grimwood J.,
RA   Richardson P., Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M.,
RA   Myers R.M., Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT VAL-564.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS LYS-392 AND THR-770.
RC   TISSUE=Brain, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [6]
RP   FUNCTION, INTERACTION WITH MDM2 AND TP53, SUBCELLULAR LOCATION,
RP   PHOSPHORYLATION AT SER-46 AND SER-63, AND MUTAGENESIS OF SER-46; SER-63 AND
RP   CYS-315.
RX   PubMed=20173098; DOI=10.1073/pnas.0912094107;
RA   Fu X., Yucer N., Liu S., Li M., Yi P., Mu J.J., Yang T., Chu J., Jung S.Y.,
RA   O'Malley B.W., Gu W., Qin J., Wang Y.;
RT   "RFWD3-Mdm2 ubiquitin ligase complex positively regulates p53 stability in
RT   response to DNA damage.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:4579-4584(2010).
RN   [7]
RP   FUNCTION, INTERACTION WITH RPA2, AND SUBCELLULAR LOCATION.
RX   PubMed=21504906; DOI=10.1074/jbc.m111.222869;
RA   Gong Z., Chen J.;
RT   "E3 ligase RFWD3 participates in replication checkpoint control.";
RL   J. Biol. Chem. 286:22308-22313(2011).
RN   [8]
RP   FUNCTION, INTERACTION WITH RPA2, SUBCELLULAR LOCATION, PHOSPHORYLATION,
RP   DEVELOPMENTAL STAGE, AND MUTAGENESIS OF CYS-315.
RX   PubMed=21558276; DOI=10.1074/jbc.m111.222802;
RA   Liu S., Chu J., Yucer N., Leng M., Wang S.Y., Chen B.P., Hittelman W.N.,
RA   Wang Y.;
RT   "RING finger and WD repeat domain 3 (RFWD3) associates with replication
RT   protein A (RPA) and facilitates RPA-mediated DNA damage response.";
RL   J. Biol. Chem. 286:22314-22322(2011).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [10]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=26474068; DOI=10.1016/j.molcel.2015.09.011;
RA   Elia A.E., Wang D.C., Willis N.A., Boardman A.P., Hajdu I., Adeyemi R.O.,
RA   Lowry E., Gygi S.P., Scully R., Elledge S.J.;
RT   "RFWD3-dependent ubiquitination of RPA regulates repair at stalled
RT   replication forks.";
RL   Mol. Cell 60:280-293(2015).
RN   [11]
RP   FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, PHOSPHORYLATION AT
RP   SER-46 AND SER-63, INVOLVEMENT IN FANCW, VARIANT FANCW LYS-639,
RP   CHARACTERIZATION OF VARIANT FANCW LYS-639, AND MUTAGENESIS OF CYS-315;
RP   GLN-499; LEU-518 AND TRP-543.
RX   PubMed=28575657; DOI=10.1016/j.molcel.2017.04.021;
RA   Feeney L., Munoz I.M., Lachaud C., Toth R., Appleton P.L., Schindler D.,
RA   Rouse J.;
RT   "RPA-mediated recruitment of the E3 ligase RFWD3 is vital for interstrand
RT   crosslink repair and human health.";
RL   Mol. Cell 66:610-621(2017).
RN   [12]
RP   FUNCTION, SUBCELLULAR LOCATION, INVOLVEMENT IN FANCW, VARIANT FANCW
RP   LYS-639, AND CHARACTERIZATION OF VARIANT FANCW LYS-639.
RX   PubMed=28691929; DOI=10.1172/jci92069;
RA   Knies K., Inano S., Ramirez M.J., Ishiai M., Surralles J., Takata M.,
RA   Schindler D.;
RT   "Biallelic mutations in the ubiquitin ligase RFWD3 cause Fanconi anemia.";
RL   J. Clin. Invest. 127:3013-3027(2017).
RN   [13]
RP   FUNCTION, CATALYTIC ACTIVITY, PHOSPHORYLATION AT SER-46 AND SER-63, AND
RP   MUTAGENESIS OF 36-LEU--PRO-38; 53-LEU--PRO-55; 70-LEU--PRO-72 AND CYS-315.
RX   PubMed=28575658; DOI=10.1016/j.molcel.2017.04.022;
RA   Inano S., Sato K., Katsuki Y., Kobayashi W., Tanaka H., Nakajima K.,
RA   Nakada S., Miyoshi H., Knies K., Takaori-Kondo A., Schindler D., Ishiai M.,
RA   Kurumizaka H., Takata M.;
RT   "RFWD3-mediated ubiquitination promotes timely removal of both RPA and
RT   RAD51 from dna damage sites to facilitate homologous recombination.";
RL   Mol. Cell 66:622-634(2017).
CC   -!- FUNCTION: E3 ubiquitin-protein ligase required for the repair of DNA
CC       interstrand cross-links (ICL) in response to DNA damage
CC       (PubMed:21504906, PubMed:21558276, PubMed:26474068, PubMed:28575657,
CC       PubMed:28575658). Plays a key role in RPA-mediated DNA damage signaling
CC       and repair (PubMed:21504906, PubMed:21558276, PubMed:26474068,
CC       PubMed:28575657, PubMed:28575658, PubMed:28691929). Acts by mediating
CC       ubiquitination of the RPA complex (RPA1, RPA2 and RPA3 subunits) and
CC       RAD51 at stalled replication forks, leading to remove them from DNA
CC       damage sites and promote homologous recombination (PubMed:26474068,
CC       PubMed:28575657, PubMed:28575658). Also mediates the ubiquitination of
CC       p53/TP53 in the late response to DNA damage, and acts as a positive
CC       regulator of p53/TP53 stability, thereby regulating the G1/S DNA damage
CC       checkpoint (PubMed:20173098). May act by catalyzing the formation of
CC       short polyubiquitin chains on p53/TP53 that are not targeted to the
CC       proteasome (PubMed:20173098). In response to ionizing radiation,
CC       interacts with MDM2 and enhances p53/TP53 ubiquitination, possibly by
CC       restricting MDM2 from extending polyubiquitin chains on ubiquitinated
CC       p53/TP53 (PubMed:20173098). {ECO:0000269|PubMed:20173098,
CC       ECO:0000269|PubMed:21504906, ECO:0000269|PubMed:21558276,
CC       ECO:0000269|PubMed:26474068, ECO:0000269|PubMed:28575657,
CC       ECO:0000269|PubMed:28575658, ECO:0000269|PubMed:28691929}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine +
CC         [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L-
CC         cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine.;
CC         EC=2.3.2.27; Evidence={ECO:0000269|PubMed:26474068,
CC         ECO:0000269|PubMed:28575657, ECO:0000269|PubMed:28575658};
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC       {ECO:0000269|PubMed:26474068, ECO:0000269|PubMed:28575657,
CC       ECO:0000269|PubMed:28575658}.
CC   -!- SUBUNIT: Interacts with MDM2 and p53/TP53 (PubMed:20173098). Binds to
CC       the RPA complex via direct interaction with RPA2 (PubMed:21504906,
CC       PubMed:21558276, PubMed:26474068, PubMed:28575658). Interacts with
CC       RAD51 (PubMed:28575658). {ECO:0000269|PubMed:20173098,
CC       ECO:0000269|PubMed:21504906, ECO:0000269|PubMed:21558276,
CC       ECO:0000269|PubMed:26474068, ECO:0000269|PubMed:28575658}.
CC   -!- INTERACTION:
CC       Q6PCD5; Q00987: MDM2; NbExp=2; IntAct=EBI-2129159, EBI-389668;
CC       Q6PCD5; Q00987-11: MDM2; NbExp=5; IntAct=EBI-2129159, EBI-5279149;
CC       Q6PCD5; P15927: RPA2; NbExp=3; IntAct=EBI-2129159, EBI-621404;
CC       Q6PCD5; P04637: TP53; NbExp=5; IntAct=EBI-2129159, EBI-366083;
CC       Q6PCD5; P61088: UBE2N; NbExp=2; IntAct=EBI-2129159, EBI-1052908;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:20173098,
CC       ECO:0000269|PubMed:21504906, ECO:0000269|PubMed:21558276,
CC       ECO:0000269|PubMed:28575657, ECO:0000269|PubMed:28691929}. Nucleus, PML
CC       body {ECO:0000269|PubMed:21558276}. Cytoplasm
CC       {ECO:0000269|PubMed:21558276, ECO:0000269|PubMed:28691929}. Note=In
CC       undamaged cells, found both in the cytoplasm and in the nucleus,
CC       partially associated with PML nuclear bodies (PubMed:21558276). In
CC       response to replication block, such as that caused by hydroxyurea
CC       treatment, or to DNA damage caused by ionizing radiations or
CC       doxorubicin, recruited to the nucleus, to stalled replication forks or
CC       to sites of DNA repair (PubMed:21504906, PubMed:28575657). This
CC       recruitment depends upon RPA2 (PubMed:21504906).
CC       {ECO:0000269|PubMed:21504906, ECO:0000269|PubMed:28575657}.
CC   -!- DEVELOPMENTAL STAGE: Up-regulated in the S-G2 phase.
CC       {ECO:0000269|PubMed:21558276}.
CC   -!- DOMAIN: The coiled coil domain may be involved in RPA2-binding.
CC       {ECO:0000269|PubMed:21558276}.
CC   -!- PTM: Phosphorylated at Ser-46 and Ser-63 upon DNA damage by ATM or ATR.
CC       ATM phosphorylation occurs at early times upon DNA damage, while ATR is
CC       the major kinase at later times. Phosphorylation by ATM and ATR is
CC       required to stabilize p53/TP53. Part of the phosphorylation depends
CC       upon RPA2 presence. {ECO:0000269|PubMed:20173098,
CC       ECO:0000269|PubMed:21558276, ECO:0000269|PubMed:28575657,
CC       ECO:0000269|PubMed:28575658}.
CC   -!- DISEASE: Fanconi anemia, complementation group W (FANCW) [MIM:617784]:
CC       A form of Fanconi anemia, a disorder affecting all bone marrow elements
CC       and resulting in anemia, leukopenia and thrombopenia. It is associated
CC       with cardiac, renal and limb malformations, dermal pigmentary changes,
CC       and a predisposition to the development of malignancies. At the
CC       cellular level it is associated with hypersensitivity to DNA-damaging
CC       agents, chromosomal instability (increased chromosome breakage) and
CC       defective DNA repair. {ECO:0000269|PubMed:28575657,
CC       ECO:0000269|PubMed:28691929}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA91662.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAF83889.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAG38132.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK001382; BAA91662.1; ALT_INIT; mRNA.
DR   EMBL; AK022673; BAB14169.1; -; mRNA.
DR   EMBL; AK291200; BAF83889.1; ALT_INIT; mRNA.
DR   EMBL; AK315786; BAG38132.1; ALT_INIT; mRNA.
DR   EMBL; AC109599; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471114; EAW95680.1; -; Genomic_DNA.
DR   EMBL; CH471114; EAW95681.1; -; Genomic_DNA.
DR   EMBL; BC002574; AAH02574.2; -; mRNA.
DR   EMBL; BC059371; AAH59371.2; -; mRNA.
DR   CCDS; CCDS32486.1; -.
DR   RefSeq; NP_060594.3; NM_018124.3.
DR   RefSeq; XP_005256078.1; XM_005256021.4.
DR   RefSeq; XP_005256079.1; XM_005256022.4.
DR   RefSeq; XP_011521493.1; XM_011523191.2.
DR   RefSeq; XP_016878880.1; XM_017023391.1.
DR   PDB; 6CVZ; X-ray; 1.80 A; A/B/C=425-774.
DR   PDBsum; 6CVZ; -.
DR   AlphaFoldDB; Q6PCD5; -.
DR   SMR; Q6PCD5; -.
DR   BioGRID; 120460; 81.
DR   DIP; DIP-52688N; -.
DR   IntAct; Q6PCD5; 50.
DR   MINT; Q6PCD5; -.
DR   STRING; 9606.ENSP00000354361; -.
DR   iPTMnet; Q6PCD5; -.
DR   PhosphoSitePlus; Q6PCD5; -.
DR   BioMuta; RFWD3; -.
DR   DMDM; 126253679; -.
DR   EPD; Q6PCD5; -.
DR   jPOST; Q6PCD5; -.
DR   MassIVE; Q6PCD5; -.
DR   MaxQB; Q6PCD5; -.
DR   PaxDb; Q6PCD5; -.
DR   PeptideAtlas; Q6PCD5; -.
DR   ProteomicsDB; 67062; -.
DR   Antibodypedia; 30261; 144 antibodies from 25 providers.
DR   DNASU; 55159; -.
DR   Ensembl; ENST00000361070.9; ENSP00000354361.4; ENSG00000168411.14.
DR   Ensembl; ENST00000571750.5; ENSP00000460049.1; ENSG00000168411.14.
DR   GeneID; 55159; -.
DR   KEGG; hsa:55159; -.
DR   MANE-Select; ENST00000361070.9; ENSP00000354361.4; NM_018124.4; NP_060594.3.
DR   UCSC; uc002fda.4; human.
DR   AGR; HGNC:25539; -.
DR   CTD; 55159; -.
DR   DisGeNET; 55159; -.
DR   GeneCards; RFWD3; -.
DR   GeneReviews; RFWD3; -.
DR   HGNC; HGNC:25539; RFWD3.
DR   HPA; ENSG00000168411; Tissue enhanced (bone).
DR   MalaCards; RFWD3; -.
DR   MIM; 614151; gene.
DR   MIM; 617784; phenotype.
DR   neXtProt; NX_Q6PCD5; -.
DR   OpenTargets; ENSG00000168411; -.
DR   Orphanet; 84; Fanconi anemia.
DR   PharmGKB; PA134960063; -.
DR   VEuPathDB; HostDB:ENSG00000168411; -.
DR   eggNOG; KOG1645; Eukaryota.
DR   GeneTree; ENSGT00390000008931; -.
DR   HOGENOM; CLU_021009_1_0_1; -.
DR   InParanoid; Q6PCD5; -.
DR   OMA; MLKLYRW; -.
DR   OrthoDB; 2788028at2759; -.
DR   PhylomeDB; Q6PCD5; -.
DR   TreeFam; TF323359; -.
DR   PathwayCommons; Q6PCD5; -.
DR   SignaLink; Q6PCD5; -.
DR   SIGNOR; Q6PCD5; -.
DR   UniPathway; UPA00143; -.
DR   BioGRID-ORCS; 55159; 121 hits in 1198 CRISPR screens.
DR   ChiTaRS; RFWD3; human.
DR   GenomeRNAi; 55159; -.
DR   Pharos; Q6PCD5; Tbio.
DR   PRO; PR:Q6PCD5; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   RNAct; Q6PCD5; protein.
DR   Bgee; ENSG00000168411; Expressed in oocyte and 141 other tissues.
DR   ExpressionAtlas; Q6PCD5; baseline and differential.
DR   Genevisible; Q6PCD5; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0016605; C:PML body; IEA:UniProtKB-SubCell.
DR   GO; GO:0090734; C:site of DNA damage; IDA:UniProtKB.
DR   GO; GO:0097371; F:MDM2/MDM4 family protein binding; IPI:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0002039; F:p53 binding; IPI:UniProtKB.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IDA:UniProtKB.
DR   GO; GO:0006974; P:DNA damage response; IDA:UniProtKB.
DR   GO; GO:0000724; P:double-strand break repair via homologous recombination; IDA:UniProtKB.
DR   GO; GO:0036297; P:interstrand cross-link repair; IMP:UniProtKB.
DR   GO; GO:0031571; P:mitotic G1 DNA damage checkpoint signaling; IMP:UniProtKB.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:2000001; P:regulation of DNA damage checkpoint; IMP:UniProtKB.
DR   GO; GO:0031297; P:replication fork processing; IDA:UniProtKB.
DR   GO; GO:0010212; P:response to ionizing radiation; IDA:UniProtKB.
DR   CDD; cd16450; mRING-C3HGC3_RFWD3; 1.
DR   Gene3D; 2.130.10.10; YVTN repeat-like/Quinoprotein amine dehydrogenase; 1.
DR   Gene3D; 3.30.40.10; Zinc/RING finger domain, C3HC4 (zinc finger); 1.
DR   InterPro; IPR037381; RFWD3.
DR   InterPro; IPR015943; WD40/YVTN_repeat-like_dom_sf.
DR   InterPro; IPR001680; WD40_repeat.
DR   InterPro; IPR036322; WD40_repeat_dom_sf.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   PANTHER; PTHR16047:SF7; E3 UBIQUITIN-PROTEIN LIGASE RFWD3; 1.
DR   PANTHER; PTHR16047; RFWD3 PROTEIN; 1.
DR   Pfam; PF13639; zf-RING_2; 1.
DR   SMART; SM00184; RING; 1.
DR   SMART; SM00320; WD40; 3.
DR   SUPFAM; SSF57850; RING/U-box; 1.
DR   SUPFAM; SSF50978; WD40 repeat-like; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Coiled coil; Cytoplasm; Disease variant; DNA damage;
KW   DNA repair; Fanconi anemia; Metal-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; Repeat; Transferase; Ubl conjugation pathway;
KW   WD repeat; Zinc; Zinc-finger.
FT   CHAIN           1..774
FT                   /note="E3 ubiquitin-protein ligase RFWD3"
FT                   /id="PRO_0000278234"
FT   REPEAT          495..537
FT                   /note="WD 1"
FT   REPEAT          539..577
FT                   /note="WD 2"
FT   REPEAT          583..628
FT                   /note="WD 3"
FT   ZN_FING         287..331
FT                   /note="RING-type; degenerate"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00175"
FT   REGION          95..116
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          139..225
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          257..280
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          361..413
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        187..223
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         46
FT                   /note="Phosphoserine; by ATM and ATR"
FT                   /evidence="ECO:0000269|PubMed:20173098,
FT                   ECO:0000269|PubMed:28575657, ECO:0000269|PubMed:28575658"
FT   MOD_RES         63
FT                   /note="Phosphoserine; by ATM and ATR"
FT                   /evidence="ECO:0000269|PubMed:20173098,
FT                   ECO:0000269|PubMed:28575657, ECO:0000269|PubMed:28575658"
FT   VARIANT         90
FT                   /note="T -> N (in dbSNP:rs8058922)"
FT                   /id="VAR_030700"
FT   VARIANT         392
FT                   /note="R -> K (in dbSNP:rs17854997)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_030701"
FT   VARIANT         564
FT                   /note="I -> V (in dbSNP:rs7193541)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_030702"
FT   VARIANT         639
FT                   /note="I -> K (in FANCW; abolishes interaction with the RPA
FT                   complex and subsequent recruitment of the protein at DNA
FT                   damage sites; decreased function in double-strand break
FT                   repair via homologous recombination; dbSNP:rs1555524842)"
FT                   /evidence="ECO:0000269|PubMed:28575657,
FT                   ECO:0000269|PubMed:28691929"
FT                   /id="VAR_078953"
FT   VARIANT         770
FT                   /note="I -> T (in dbSNP:rs17854996)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_030703"
FT   MUTAGEN         36..38
FT                   /note="LQP->AAA: Decreased interaction with RAD51; when
FT                   associated with 53-A--A-55 and 70-A--A-72."
FT                   /evidence="ECO:0000269|PubMed:28575658"
FT   MUTAGEN         46
FT                   /note="S->A: Markedly decreases phosphorylation following
FT                   ionizing radiation and abolishes ability to stimulate
FT                   p53/TP53 ubiquitination; when associated with A-63."
FT                   /evidence="ECO:0000269|PubMed:20173098"
FT   MUTAGEN         53..55
FT                   /note="LQP->AAA: Decreased interaction with RAD51; when
FT                   associated with 36-A--A-38 and 70-A--A-72."
FT                   /evidence="ECO:0000269|PubMed:28575658"
FT   MUTAGEN         63
FT                   /note="S->A: Markedly decreases phosphorylation following
FT                   ionizing radiation and abolishes ability to stimulate
FT                   p53/TP53 ubiquitination; when associated with A-46."
FT                   /evidence="ECO:0000269|PubMed:20173098"
FT   MUTAGEN         70..72
FT                   /note="LQP->AAA: Decreased interaction with RAD51; when
FT                   associated with 36-A--A-38 and 53-A--A-55."
FT                   /evidence="ECO:0000269|PubMed:28575658"
FT   MUTAGEN         315
FT                   /note="C->A: Abolishes ability to stimulate p53/TP53
FT                   ubiquitination. No effect on nuclear localization in
FT                   response to DNA damage."
FT                   /evidence="ECO:0000269|PubMed:20173098,
FT                   ECO:0000269|PubMed:21558276, ECO:0000269|PubMed:28575657,
FT                   ECO:0000269|PubMed:28575658"
FT   MUTAGEN         499
FT                   /note="Q->A: Does not affect interaction with the RPA
FT                   complex and subsequent recruitment at DNA damage sites."
FT                   /evidence="ECO:0000269|PubMed:28575657"
FT   MUTAGEN         518
FT                   /note="L->A: Does not affect interaction with the RPA
FT                   complex and subsequent recruitment at DNA damage sites."
FT                   /evidence="ECO:0000269|PubMed:28575657"
FT   MUTAGEN         543
FT                   /note="W->A: Abolishes interaction with the RPA complex and
FT                   subsequent recruitment at DNA damage sites."
FT                   /evidence="ECO:0000269|PubMed:28575657"
FT   CONFLICT        221
FT                   /note="S -> P (in Ref. 1; BAF83889)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        552
FT                   /note="A -> T (in Ref. 1; BAA91662)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        597
FT                   /note="A -> V (in Ref. 1; BAA91662)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        741
FT                   /note="Q -> R (in Ref. 1; BAB14169)"
FT                   /evidence="ECO:0000305"
FT   STRAND          435..443
FT                   /evidence="ECO:0007829|PDB:6CVZ"
FT   STRAND          453..456
FT                   /evidence="ECO:0007829|PDB:6CVZ"
FT   TURN            457..460
FT                   /evidence="ECO:0007829|PDB:6CVZ"
FT   STRAND          461..467
FT                   /evidence="ECO:0007829|PDB:6CVZ"
FT   TURN            470..472
FT                   /evidence="ECO:0007829|PDB:6CVZ"
FT   STRAND          475..483
FT                   /evidence="ECO:0007829|PDB:6CVZ"
FT   TURN            484..487
FT                   /evidence="ECO:0007829|PDB:6CVZ"
FT   STRAND          491..498
FT                   /evidence="ECO:0007829|PDB:6CVZ"
FT   STRAND          500..505
FT                   /evidence="ECO:0007829|PDB:6CVZ"
FT   STRAND          507..509
FT                   /evidence="ECO:0007829|PDB:6CVZ"
FT   STRAND          512..517
FT                   /evidence="ECO:0007829|PDB:6CVZ"
FT   STRAND          520..526
FT                   /evidence="ECO:0007829|PDB:6CVZ"
FT   TURN            527..530
FT                   /evidence="ECO:0007829|PDB:6CVZ"
FT   STRAND          531..537
FT                   /evidence="ECO:0007829|PDB:6CVZ"
FT   STRAND          542..547
FT                   /evidence="ECO:0007829|PDB:6CVZ"
FT   STRAND          550..552
FT                   /evidence="ECO:0007829|PDB:6CVZ"
FT   STRAND          554..559
FT                   /evidence="ECO:0007829|PDB:6CVZ"
FT   STRAND          564..568
FT                   /evidence="ECO:0007829|PDB:6CVZ"
FT   STRAND          572..574
FT                   /evidence="ECO:0007829|PDB:6CVZ"
FT   STRAND          576..579
FT                   /evidence="ECO:0007829|PDB:6CVZ"
FT   STRAND          588..594
FT                   /evidence="ECO:0007829|PDB:6CVZ"
FT   STRAND          606..611
FT                   /evidence="ECO:0007829|PDB:6CVZ"
FT   STRAND          614..620
FT                   /evidence="ECO:0007829|PDB:6CVZ"
FT   STRAND          626..630
FT                   /evidence="ECO:0007829|PDB:6CVZ"
FT   STRAND          635..644
FT                   /evidence="ECO:0007829|PDB:6CVZ"
FT   TURN            645..648
FT                   /evidence="ECO:0007829|PDB:6CVZ"
FT   STRAND          649..660
FT                   /evidence="ECO:0007829|PDB:6CVZ"
FT   STRAND          664..674
FT                   /evidence="ECO:0007829|PDB:6CVZ"
FT   STRAND          680..691
FT                   /evidence="ECO:0007829|PDB:6CVZ"
FT   STRAND          703..706
FT                   /evidence="ECO:0007829|PDB:6CVZ"
FT   STRAND          714..718
FT                   /evidence="ECO:0007829|PDB:6CVZ"
FT   STRAND          725..730
FT                   /evidence="ECO:0007829|PDB:6CVZ"
FT   TURN            731..733
FT                   /evidence="ECO:0007829|PDB:6CVZ"
FT   STRAND          736..741
FT                   /evidence="ECO:0007829|PDB:6CVZ"
FT   STRAND          748..754
FT                   /evidence="ECO:0007829|PDB:6CVZ"
FT   STRAND          757..763
FT                   /evidence="ECO:0007829|PDB:6CVZ"
FT   STRAND          765..774
FT                   /evidence="ECO:0007829|PDB:6CVZ"
SQ   SEQUENCE   774 AA;  85094 MW;  EF6E0E186FD2E580 CRC64;
     MAHEAMEYDV QVQLNHAEQQ PAPAGMASSQ GGPALLQPVP ADVVSSQGVP SILQPAPAEV
     ISSQATPPLL QPAPQLSVDL TEVEVLGEDT VENINPRTSE QHRQGSDGNH TIPASSLHSM
     TNFISGLQRL HGMLEFLRPS SSNHSVGPMR TRRRVSASRR ARAGGSQRTD SARLRAPLDA
     YFQVSRTQPD LPATTYDSET RNPVSEELQV SSSSDSDSDS SAEYGGVVDQ AEESGAVILE
     EQLAGVSAEQ EVTCIDGGKT LPKQPSPQKS EPLLPSASMD EEEGDTCTIC LEQWTNAGDH
     RLSALRCGHL FGYRCISTWL KGQVRKCPQC NKKARHSDIV VLYARTLRAL DTSEQERMKS
     SLLKEQMLRK QAELESAQCR LQLQVLTDKC TRLQRRVQDL QKLTSHQSQN LQQPRGSQAW
     VLSCSPSSQG QHKHKYHFQK TFTVSQAGNC RIMAYCDALS CLVISQPSPQ ASFLPGFGVK
     MLSTANMKSS QYIPMHGKQI RGLAFSSYLR GLLLSASLDN TIKLTSLETN TVVQTYNAGR
     PVWSCCWCLD EANYIYAGLA NGSILVYDVR NTSSHVQELV AQKARCPLVS LSYMPRAASA
     AFPYGGVLAG TLEDASFWEQ KMDFSHWPHV LPLEPGGCID FQTENSSRHC LVTYRPDKNH
     TTIRSVLMEM SYRLDDTGNP ICSCQPVHTF FGGPTCKLLT KNAIFQSPEN DGNILVCTGD
     EAANSALLWD AASGSLLQDL QTDQPVLDIC PFEVNRNSYL ATLTEKMVHI YKWE
//
